News provided by
Share this article
Share this article
GQ1010 demonstrated greater tumor growth inhibition and more potent cytotoxicity than DS-1062 across several preclinical models
GQ1010 in combination with anti-PD1 also showed synergistic in vivo tumor growth inhibition superior to DS-1062 plus anti-PD1
Differentiated preclinical safety profile of GQ1010 suggests potential for a wider therapeutic index and improved combinability compared to more advanced TROP2 ADCs
BRIDGEWATER, N.J., April 18, 2023 /PRNewswire/ -- Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, and its partner GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, announced data at the American Association for Cancer Research (AACR) Annual Meeting 2023 highlighting the preclinical efficacy and safety profile of GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), across several in vitro and in vivo models. The poster presentation highlights several preclinical studies which showcase the differentiating attributes of GQ1010. Specifically, in a mouse syngeneic MC38 colon cancer model, the combination of GQ1010 plus anti-PD-1 therapy showed compelling synergistic tumor growth inhibition, which was superior to DS-1062 plus anti-PD-1. In this study, the GQ1010 combination reported 5 of 6 animals achieved a complete response, compared to zero of 6 animals with the DS-1062 combination. In addition, GQ1010 showed more potent in vitro cytotoxicity and a superior bystander effect versus DS-1062, and increased in vivo tumor growth inhibition with GQ1010 monotherapy compared head-to-head with either DS-1062 or TRODELVY® across multiple cancer models. Safety findings with GQ1010 in a non-human primate (NHP) study indicated a differentiated profile and highest non-severe toxic dose (HNSTD) of greater than 30 mg/kg, which may translate to a wider therapeutic window in human studies relative to more advanced TROP2 ADCs in development. Plasma stability studies showed 98% retention of drug-to-antibody ratio (DAR) for GQ1010, attributable to its unique, irreversible cleavable linker chemistry. "These preclinical findings are driven by GQ1010's unique ADC design, which utilizes site-specific enzymatic conjugation technology and a novel linker-payload which confer potent cytotoxicity and better stability in the plasma," said Qin Gang, Ph.D., CEO of GeneQuantum Healthcare. "The preclinical differentiation seen with GQ1010 provides further validation of the capabilities of the GeneQuantum platform to produce best-in-class bioconjugates, as was also observed in a Phase 1a study of the HER2-directed ADC, GQ1001." "TROP2 is a highly validated target in oncology, and TROP2-directed therapies are an important potential treatment option for a large number of cancers," remarked Brian Lestini, MD PhD, CEO of Pyramid Biosciences. "However, despite the TROP2 agents currently approved or in development, there remains significant unmet need for therapies that improve efficacy while reducing the potential for serious toxicities and optimizing therapeutic index and combinability. Preclinical data demonstrates the potential for GQ1010's unique ADC chemistry to provide a superior, best-in-class clinical profile and improve patient outcomes. Based on this preclinical data, we are excited to be moving GQ1010 into clinical development." The AACR annual meeting poster presentation details are as follows:
Title: Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2 positive solid tumors
First Author: Yajun Sun
Abstract #: 1549
About TROP2
TROP2 is a cell surface glycoprotein that is highly expressed in a variety of tumors including breast, lung, pancreatic, ovarian, and prostate cancer, and plays a role in tumor cell proliferation. Currently TRODELVY® (Gilead) is the only approved TROP2 ADC, with indications in triple-negative breast cancer, hormone-receptor positive breast cancer, and urothelial cancer. Clinical data have also been previously reported for TROP2 ADCs in development by Daiichi-Sankyo and Merck & Co.
About Pyramid Biosciences, Inc. Founded in 2015, Pyramid Biosciences, Inc. is a clinical stage biotechnology company dedicated to developing transformative medicines for patients with cancer. Pyramid focuses on programs that target clinically validated mechanisms and with potential best-in-class properties that can address areas of high unmet need in cancer. Pyramid is currently conducting a global Phase 1/2 clinical trial of its lead oncology program PBI-200, a highly CNS penetrant next-generation NTRK inhibitor, in patients with NTRK-fusion driven cancers including primary and metastatic brain tumors. For more information, please visit www.pyramidbio.com . Pyramid Biosciences Media Inquiries:
Laura DiCaprio

Pyramid Biosciences and GeneQuantum Healthcare Announce Preclinical Data for GQ1010, a Potential Best-In-Class TROP2-Targeted Antibody Drug Conjugate, at the 2023 AACR Annual Meeting

News provided by
Share this article
GQ1010 preclinical profile demonstrates potential for differentiation vs other TROP2 ADCs
Proprietary GeneQuantum platform provides single-step site-specific enzymatic conjugation and potential for superior linker-payload technology vs conventional ADCs
BRIDGEWATER, N.J., April 13, 2023 /PRNewswire/ -- Pyramid Biosciences, Inc. , a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, today announced that it has entered into an exclusive license agreement with GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, to develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan). GQ1010 has shown a highly differentiated preclinical profile, and is anticipated to enter a first-in-human trial within the next 12 months. "We are thrilled to be partnering with GeneQuantum in bringing this exciting asset, GQ1010, into the clinic," said Brian Lestini, M.D., Ph.D., Chief Executive Officer of Pyramid Biosciences. "By leveraging the unique features of the GeneQuantum bioconjugation platform and Pyramid's deep expertise in oncology drug development, this partnership significantly expands our growing oncology portfolio. This highly differentiated program has the potential to address substantial limitations of current ADCs and unmet needs for patients with TROP2-expressing tumors, a clinically validated target in oncology." "GeneQuantum was founded with the goal of addressing critical unmet needs in global healthcare through the development of innovative technologies. GQ1010 highlights its best-in-class potential through GeneQuantum's cutting-edge technology in the development of differentiated bioconjugate drugs such as GQ1001, an anti-HER2 ADC, which has demonstrated a differentiated profile in Phase 1 data. We believe this agreement between GeneQuantum and Pyramid Biosciences represents the ideal partnership to rapidly advance the worldwide development of GQ1010, and to help patients overcome their cancer," said Qin Gang, Ph.D., Chief Executive Officer of GeneQuantum. "Our collaboration with Pyramid for global development of the GQ1010 program brings together the best of GeneQuantum's proprietary technology and Pyramid's extensive capabilities and track record of success in delivering transformative medicines to patients with cancer." GQ1010 utilizes a unique site-specific conjugation technology and incorporates a novel linker-payload which may lead to improved stability, safety and potency of the ADC. Preclinical data suggests GQ1010 has a broader therapeutic margin compared to more advanced TROP2 ADCs, that may translate to an improved efficacy and safety profile for GQ1010. TROP2 is a cell surface glycoprotein that is highly expressed in a variety of tumors including breast, lung, pancreatic, ovarian, and prostate cancer, and plays a role in tumor cell proliferation. Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010 in exchange for an upfront payment of $20 million and up to an additional $1 billion of milestone payments. GeneQuantum would also be eligible to receive tiered royalties ranging from mid-single digit to low double digits on net sales. About Pyramid Biosciences, Inc. Founded in 2015, Pyramid Biosciences, Inc. is a New Jersey-based, clinical stage, biotechnology company dedicated to developing transformative medicines for patients with cancer. Pyramid focuses on programs that target clinically validated mechanisms and with potential best-in-class properties that can address areas of high unmet need in cancer. Pyramid's lead oncology program PBI-200, a highly CNS penetrant next-generation NTRK inhibitor is currently in a global Phase 1/2 clinical trial in patients with NTRK-fusion driven cancers, including primary and metastatic brain tumors. For more information, please visit www.pyramidbio.com . Pyramid Biosciences Media Inquiries:

Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare

January 18, 2023 07:35 AM Eastern Standard Time
WALTHAM, Mass.--( BUSINESS WIRE )--Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, has announced its participation this week in the B. Riley Securities 3rd Annual Oncology Conference. Its Chief Executive Officer, Dr. Brian Lestini, will present on Thursday, January 19, 2023, at 2 PM ET. The conference will feature more than 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities. Highlights include panel discussions with academic and industry key opinion leaders at the forefront of translational and clinical research. Topics span novel immunotherapy, cell therapy, and targeted oncology approaches, as well as imaging and radiation oncology initiatives aimed at driving meaningful improvements to current standard of care for cancer patients. Additional information regarding the event and registration is available through the conference website: https://brileyoncology22.sequireevents.com/ . About Pyramid Biosciences, Inc. Founded in 2015, Pyramid Biosciences, Inc. is a Boston-based, clinical stage, biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly-defined diseases, regulated by the tropomyosin receptor kinase (TRK) family. Pyramid's lead clinical program, PBI-200, is a novel, highly brain-penetrant, potential best-in-class TRK inhibitor for patients with NTRK-driven cancers. For more information, please visit www.pyramidbio.com . Contacts

Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference

November 03, 2022 07:00 AM Eastern Daylight Time
WALTHAM, Mass.--( BUSINESS WIRE )--Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, announced today that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT. A live webcast of the presentation will be accessible on Pyramid’s website at Jefferies audiocast link or by visiting: https://wsw.com/webcast/jeff255/pyrb/1873179 . A replay of the call will be archived for 90 days after the call. For more information on the conference or to schedule a one-on-one meeting with the Pyramid Biosciences management, please contact your Jefferies representative. Founded in 2015, Pyramid Biosciences, Inc. is a Boston-based, clinical stage, biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Pyramid lead clinical program, PBI-200, is a novel, highly brain-penetrant, potential best-in-class TRK inhibitor for patients with NTRK-driven cancers. For more information, please visit www.pyramidbio.com . Contacts

Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference

Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)-- #PyramidBiosciences --Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, announced today that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT. A live webcast of the presentation will be accessible on Pyramid’s website at Jefferies audiocast link or by visiting: https://wsw.com/webcast/jeff255/pyrb/1873179 . A replay of the call will be archived for 90 days after the call. For more information on the conference or to schedule a one-on-one meeting with the Pyramid Biosciences management, please contact your Jefferies representative. Founded in 2015, Pyramid Biosciences, Inc. is a Boston-based, clinical stage, biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Pyramid lead clinical program, PBI-200, is a novel, highly brain-penetrant, potential best-in-class TRK inhibitor for patients with NTRK-driven cancers. For more information, please visit www.pyramidbio.com . Contacts
Elizabeth Harness, senior consultant: elizabeth@mcdougallpr.com
Pyramid Biosciences Investor Inquiries:
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us
Version: 2022.9.21.3
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com. PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Continue

GeneQuantum Healthcare is a company that focuses on the research and development of bio-therapeutics. The company's technology uses a ligase-dependent conjugation platform. It is based in Jiangsu, China.

GeneQuantum Healthcare

We believe this agreement between GeneQuantum Healthcare and Pyramid Biosciences , Inc. represents the ideal partnership to rapidly advance the worldwide development of GQ1010 , and to help patients overcome their cancer , '' said Qin Gang , Ph.D. , Chief Executive Officer of GeneQuantum Healthcare .

Caris focuses on molecular science, specifically in the domain of cancer care. The company offers services such as molecular profiling, blood profiling, and tissue profiling, which provide comprehensive molecular information to help oncologists create personalized treatment plans for cancer patients. It primarily sells to the healthcare industry, particularly oncology. It was founded in 2008 and is based in Irving, Texas.

Caris

AstraZeneca (LON: AZN) operates as a research-based biopharmaceutical company in the healthcare sector. The company's main offerings include innovative medicines in areas such as oncology, cardiovascular, renal, metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. It was founded in 1999 and is based in Cambridge, United Kingdom.

AstraZeneca

Safeguard Scientifics

MentorTech Ventures

Pharos Capital Group

Pfizer

Series A

Series A - II

Series A - III

Series A - IV

Series B

Pyramid Biosciences is a clinical-stage biotechnology company with a focus on oncology. The company develops targeted therapies aimed at improving the lives of patients with cancer. It primarily serves the healthcare and biotechnology industries. It was founded in 2015 and is based in Waltham, Massachusetts.

Name	Work History	Title	Status
Jordan Leef	Safeguard Scientifics, MentorTech Ventures, Pharos Capital Group, and Pfizer	Founder	Current
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

Name	Jordan Leef	Subscribe to see more
Work History	Safeguard Scientifics, MentorTech Ventures, Pharos Capital Group, and Pfizer	Subscribe to see more
Title	Founder	Subscribe to see more
Status	Current	Subscribe to see more

Wells Fargo Success Story

Professional Services

Platform Overview

Pyramid Biosciences

Executives

Pyramid Biosciences Management Team

2 Team Members